Hologic (NSDQ:HOLX) announced that it acquired fibroid treatment developer Acessa Health in a deal worth approximately $80 million.
Austin, Texas-based Acessa markets the Acessa ProVu fully integrated laparoscopic system for combining radiofrequency ablation with intra-abdominal ultrasound visualization and guidance mapping for treating women with symptomatic, benign uterine fibroids.
Marlborough, Mass.-based Hologic said in a news release that the Acessa ProVu system will complement its market-leading MyoSure products designed for the hysteroscopic removal of fibroids found in the uterine cavity.
The deal includes $80 million in cash, plus additional contingent payments based on future revenue growth, according to the release. Hologic estimates that Acessa Health will generate approximately $13 million in revenue for fiscal 2021, producing a slightly dilutive impact on Hologic’s non-Gaap earnings per share for the year, then a break-even in 2022, …